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the optimal vascular access type for elderly hemodialysis patients is controversial. We evaluated the 
impact of comorbidity burden on the association between vascular access type and mortality risk 
among 23,100 hemodialysis patients aged ≥65 years from the Korean Society of Nephrology End-Stage 
Renal Disease registry data. Subjects were stratified into tertiles according to the simplified Charlson 
comorbidity index (scci), and the survival and hospitalization rates were compared with respect 
to vascular access type: arteriovenous fistula (AVF), arteriovenous graft (AVG), and central venous 
catheter (cVc). Among all tertiles of scci, cVc use showed highest risk of mortality than AVf use. in the 
lowest to middle tertile, no difference was observed in survival rates between the use of AVF and AVG. 
However, in the highest tertile, AVG use showed higher risk of mortality than AVF use. When subjects 
were classified according to a combination of sCCI tertile and access type (AVF vs. AVG), patients with 
the highest CCI with AVG showed 1.75-folded increased risk of mortality than those with the lowest sCCI 
with AVf. Hospitalization rates due to access malfunction were highest in patients with cVc in all scci 
tertiles. In the highest tertile, patients with AVG showed increased rates of hospitalization compared to 
those with AVf due to access malfunction. However, hospitalization rates due to access infection were 
highest in patients with AVG in all tertiles. The use of AVF may be of benefit and switching to AVF should 
be considered in elderly hemodialysis patients with a high burden of comorbidity.
The prevalence of elderly patients with end-stage renal disease (ESRD) is increasing worldwide1. In Korea, the 
primary treatment for geriatric ESRD is hemodialysis (HD, 81.3% of elderly patients)2. The average age of dialysis 
patients was 61.2 ± 14.5 years in 2016, which has steadily increased from 55.2 years in 20053. The percentage of 
elderly dialysis patients in Korea (over 65 years old) was 43.9% in 2016, representing a significant increase from 
28% in 2005. Accordingly, the associated range of comorbidities and geriatric syndromes such as frailty is also 
increasing, and the higher burden of comorbidity makes elderly patients more prone to adverse outcomes after 
dialysis initiation4–6. Although nephrologists take great effort to improve their prognosis, there are still no clear 
guidelines established for adequate dialysis prescription in elderly dialysis patients.
The selection of the most optimal type of vascular access for elderly patients undergoing HD is controversial, 
and several underlying comorbidities make this selection difficult. In the majority of elderly patients, HD is ini-
tiated with a central venous catheter (CVC) with a subsequent switch to the placement of a permanent vascular 
access device, either an arteriovenous fistula (AVF) or an arteriovenous graft (AVG)1. Previous studies suggest 
that placement of an AVF is preferred over placement of an AVG7,8. These suggestions are based on the obser-
vation that AVFs result in better long-term survival and require fewer interventions to maintain their patency 
as compared with AVGs. However, the advantages of AVFs over AVGs may be less apparent in elderly patients 
undergoing HD. Maturation of AVF is much slower in elderly patients compared with younger patients, and 
the high burden of comorbidity in elderly patients may contribute to a high rate of AVF non-maturation9,10. 
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In addition, elderly patients have shorter life expectancies, which means that they may not live long enough to see 
the benefits of prolonged AVF survival11.
Considering the range of comorbidities is thus crucial when choosing and maintaining the proper vascular 
access type in elderly patients undergoing HD. This study aimed to evaluate the impact of comorbidity burden on 
the association between vascular access type and mortality risk among elderly patients undergoing HD.
Results
Baseline characteristics. Baseline characteristics of the study subjects are presented in Table 1. The mean 
age was 73.7 ± 6.0 years, and 56.1% of patients were men. The mean of dialysis vintage was 3.8 ± 3.3 years, and 
the most common cause of ESRD among all study subjects was diabetic nephropathy (51.1%). We classified 
study subjects according to the type of vascular access: AVF (n = 14,847), AVG (n = 3,906), and CVC (n = 4,347). 
Patients using AVF or AVG tended to be younger, were more likely to be male, and had higher body mass index 
(BMI) and normalized protein catabolic rate (nPCR) compared with those using CVC. The mean dialysis vin-
tage was shorter in patients with CVC than in patients with AVF or AVG. There were no differences in levels of 
single-pool Kt/V and predialysis systolic or diastolic blood pressures (SBP or DBP) among groups. Patients with 
Total
(n = 23,100)
Type of vascular access
P
AVF
(n = 14,847)
AVG
(n = 3,906)
CVC
(n = 4,347)
Demographic data
  Age, years 73.7 ± 6.0 73.0 ± 5.7 74.3 ± 5.9 75.9 ± 6.6 <0.001
  Gender, male 12,948 (56.1) 8,672 (58.4) 2,037 (52.2) 2,239 (51.5) <0.001
  BMI, kg/m2 22.2 ± 4.3 22.3 ± 3.8 21.9 ± 3.2 21.8 ± 6.7 <0.001
  Dialysis vintage, year 3.8 ± 3.3 4.2 ± 3.4 3.7 ± 3.2 2.5 ± 2.6 <0.001
  nPCR, g/kg/day 0.4 ± 0.9 0.4 ± 0.9 0.3 ± 0.6 0.3 ± 0.6 <0.001
  Single-pool Kt/V 1.49 [1.28–1.78]
1.49 
[1.28–1.77]
1.53 
[1.32–1.79]
1.49 
[1.26–1.82] 0.07
  SBP, mmHg 138.9 ± 24.3 138.8 ± 24.9 139.8 ± 24.6 138.2 ± 21.2 0.08
  DBP, mmHg 73.4 ± 16.3 13.6 ± 14.6 72.6 ± 23.9 73.7 ± 12.3 0.03
  Functional status <0.001
   Inability to ambulate 1,508 (11.1) 603 (7.0) 268 (11.1) 637 (24.2)
    Need of assistance with 
daily activities 4,394 (32.3) 2,441 (28.5) 873 (36.3) 1,080 (41.0)
   Independently living 7,696 (56.2) 5,514 (64.4) 1,266 (52.6) 916 (34.8)
  Etiology of ESRD <0.001
   Diabetic nephropathy 11,804 (51.1) 7,696 (51.8) 2,047 (52.4) 2,061 (47.4)
   Hypertension 5,436 (23.5) 3,482 (23.5) 954 (24.4) 1,000 (23.0)
   Glomerulonephritis 1,327 (5.7) 920 (6.2) 166 (4.2) 241 (5.5)
   Polycystic kidney disease 275 (1.2) 198 (1.3) 44 (1.1) 33 (0.8)
   Other 1,329 (5.8) 741 (5.0) 204 (5.2) 384 (8.8)
   Unknown 2,929 (12.7) 1,810 (12.2) 491 (12.6) 628 (14.4)
  sCCI 5.8 ± 1.1 5.7 ± 1.1 5.9 ± 1.1 6.0 ± 1.2 <0.001
Comorbidities
  Hypertension 11,804 (51.1) 7,696 (51.8) 2,047 (52.4) 2,061 (47.4) <0.001
  Diabet®es 9,027 (39.1) 5,984 (40.3) 1,604 (41.1) 1,439 (33.1) <0.001
  Coronary artery disease 3,136 (13.6) 2,077 (14.0) 538 (13.8) 521 (12.0) 0.002
  Congestive heart failure 1,563 (6.8) 968 (6.5) 279 (7.1) 316 (7.3) 0.05
  Cerebrovascular disease 1,428 (6.2) 867 (5.8) 254 (6.5) 307 (7.1) 0.002
  Malignancy 656 (2.8) 413 (2.8) 99 (2.5_ 144 (3.3) 0.14
Laboratory findings
  Hemoglobin, g/dL 10.1 ± 3.0 10.2 ± 3.2 10.2 ± 3.2 9.8 0 ± 1.4 <0.001
  Albumin, g/dL 3.8 ± 0.6 3.9 ± 0.6 3.8 ± 0.6 3.5 ± 0.7 <0.001
  Total cholesterol, mg/dL 142.7 ± 39.5 142.5 ± 38.7 142.7 ± 38.9 143.5 ± 42.7 0.55
  HbA1c, % 6.6 ± 7.2 6.7 ± 8.5 6.4 ± 2.5 6.3 ± 4.7 0.19
  Calcium, mg/dL 8.7 ± 0.8 8.7 ± 0.9 8.7 ± 0.8 8.5 ± 0.9 <0.001
  Phosphorous, mg/dL 4.3 ± 1.4 4.4 ± 1.4 4.2 ± 1.4 4.0 ± 1.5 <0.001
  intact-PTH, pg/mL 160.0 ± 148.7 162.6 ± 152.8 150.1 ± 132.4 159.9 ± 148.2 0.001
Table 1. Baseline characteristics according to type of vascular access. Data were presented as mean ± standard 
deviation, median [interquartile range] or number (%). Abbreviation: AVF, arteriovenous fistula; AVG, 
arteriovenous graft; CVC, central venous catheter; BMI, body mass index; ESRD, end-stage renal disease; sCCI, 
simplified Charlson comorbidity index; PTH, parathyroid hormone. 
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AVF or AVG showed better functional status than those with CVC. The mean of the simplified CCI (sCCI) was 
5.8 ± 1.1 among all patients. The sCCI was lowest in patients with AVF and highest in those with CVC (5.7 ± 1.1, 
5.9 ± 1.1, and 6.0 ± 1.2 in AVF, AVG, and CVC, respectively, P < 0.001) However, patients using AVF or AVG 
had higher prevalence of diabetes, hypertension, and coronary artery disease but lower prevalence rates of cere-
brovascular disease than those with CVC. In laboratory tests, patients with AVF or AVG showed higher levels of 
hemoglobin and serum albumin compared to those with CVC.
current state of vascular access use according to the comorbidity burden. Next, we compared 
the current state of vascular access use according to sCCI. In all cases, the prevalence of AVF use was the highest 
(68.9%, 61.9%, and 59.3% in the lowest, middle, and highest sCCI groups). However, in higher sCCI groups, the 
use of AVF was lower, and the use of AVG and CVC was significantly higher (Fig. 1).
Vascular access type and all-cause mortality. We assessed the association between vascular access 
type and all-cause mortality according to sCCI groups. During a median follow-up of 3.8 [2.1–6.1] years, 4,405 
(19.1%) deaths occurred. First, we plotted Kaplan-Meier curves for the risk of all-cause mortality according to the 
type of vascular access at different levels of sCCI (Fig. 2A–C). In all cases, the use of AVF showed the best survival 
rates, and the use of CVC showed the worst rates. In multivariable Cox analysis after adjustment for age, sex, 
dialysis vintage, BMI, predialysis SBP, etiology of ESRD, functional status, history of hypertension, diabetes, or 
cardiovascular diseases (CVDs), hemoglobin, serum albumin, and HbA1c, the use of CVC still showed the high-
est risk of all-cause mortality in all sCCI groups compared with the use of AVF. However, the use of AVG showed 
a greater risk of all-cause mortality than AVF only in patients in the highest sCCI group (hazard ratio [HR], 1.33; 
95% confidence interval [CI], 1.02–1.75, P = 0.04) (Table 2).
Comparison of the use of AVF vs. AVG according to the comorbidity burden. Next, we further 
compared the risk of mortality between the use of AVF and AVG according to sCCI tertiles. We formed six groups 
based on the combination of AVF or AVG and sCCI tertiles. The incidence of all-cause mortality was higher in 
higher sCCI groups. Moreover, in all equivalent sCCI groups, the use of AVG showed higher mortality rates 
than the use of AVF (Supplementary Table 1). Multivariable Cox analysis was performed after adjustment for 
confounding factors, and the results indicated that patients using AVG in the highest sCCI tertile was associated 
with 75% increased risk of all-cause mortality compared with those using AVF in the lowest sCCI (HR, 1.75; 95% 
CI, 1.20–2.50, P = 0.004) (Fig. 3).
Vascular access type and hospitalization rate according to comorbidity burden. To evaluate 
the association between the rate of hospitalization and vascular access type according to the sCCI, we performed 
logistic regression analysis (Table 3). The number of hospitalizations due to all causes was highest in patients 
using CVC, followed by AVG and AVF. We separately analyzed the risk of hospitalization based on the cause, 
that is, either access malfunction or access infection. The total events of hospitalization due to access malfunction 
occurred in 1,061 cases (4.6%) and that of hospitalization due to access infection occurred in 180 cases (0.8%). 
The risk of hospitalization due to access malfunction was highest in patients using CVC compared with those 
using AVF in all sCCI tertiles. However, while no association was observed between patients with AVG in the 
lowest to middle sCCI groups and those with AVF, patients with AVG in the highest sCCI group showed a sig-
nificantly increased risk of hospitalization due to access malfunction (odds ratio [OR], 1.74; 95% CI 1.04–2.92; 
P = 0.03). In contrast, the risk of hospitalization due to access infection was not associated with the use of CVC 
in any sCCI tertiles, whereas the use of AVG was significantly associated with increased risk in all CCI tertiles 
Figure 1. Percentage use of vascular access according to tertiles of sCCI. X axis represents tertiles of sCCI, P for 
trend <0.001. Abbreviation: CVC, central venous catheter; AVG, arteriovenous graft; AVF, arteriovenous fistula; 
sCCI, simplified Charlson comorbidity index.
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compared with the use of AVF (HR, 4.41; 95% 1.35–14.45 in lowest sCCI, HR, 5.00; 95% CI, 1.57–15.90 in middle 
sCCI, and HR, 3.90; 95% CI, 1.47–10.32 in highest sCCI tertile).
Discussion
This study compared the risk of all-cause mortality and hospitalization rates due to catheter malfunction or infec-
tion based on maintenance of vascular access type at different levels of comorbidity burden in elderly patients 
undergoing HD. As sCCI increased, the use of AVF was lower, while use of AVG and CVC was higher. In all sCCI 
tertiles, the use of CVC was associated with the highest risk of all-cause mortality compared to the use of AVF. 
The use of AVG vs. AVF showed no differences in risk of mortality in the lowest to middle sCCI tertiles. However, 
in the highest sCCI tertile, the use of AVG showed a higher risk of all-cause mortality than the use of AVF. 
Furthermore, hospitalization rates due to access malfunction were higher with the use of CVC in all sCCI tertiles, 
whereas hospitalization rates due to access infection were higher with use of AVG compared with use of AVF.
Currently, the international clinical practice guidelines recommend a “fistula first” approach based on the best 
long-term outcomes, lowest mortality, and lowest health care costs of AVF compared with AVG and CVC12–15. 
Several observational studies with elderly patients also demonstrated superior survival rates in those using AVF 
compared with AVG and CVC16,17. However, another study reported that there is no significant survival benefit in 
the different vascular access types18. Recently, Lee et al.19 suggested tradeoffs in vascular access selection in elderly 
patients initiating HD. They suggested that the use of AVF, compared with the use of AVG, is less likely to be suc-
cessful after initiation, more likely to require interventions to make it functional, and associated with longer CVC 
dependence. In contrast, AVF requires fewer interventions to maintain patency after successful access creation. 
Hence, the optimal type of vascular access for elderly patients undergoing HD is still controversial, and several 
factors make selection of the best type of access difficult. In elderly patients undergoing HD, the geriatric barriers 
Figure 2. Kaplan-Meier curve for the risk of all-cause mortality according to type of vascular access st different 
levels of sCCI. Abbreviation: CVC, central venous catheter; AVG, arteriovenous graft; AVF, arteriovenous fistula; 
sCCI, simplified Charlson comorbidity index.
Model 1 Model 2 Model 3
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Lowest tertile of sCCI (4–5)
AVF (n = 6,748) 1.00 (reference) 1.00 (reference) 1.00 (reference)
AVG (n = 1,515) 1.29 (1.12–1.48) <0.001 1.24 (1.08–1.42) 0.002 1.04 (0.67–1.63) 0.86
CVC (n = 1,528) 4.05 (3.54–4.63) <0.001 2.45 (2.14–2.81) <0.001 2.81 (1.90–4.16) <0.001
Middle tertile of sCCI (6)
AVF (n = 5,041) 1.00 (reference) 1.00 (reference) 1.00 (reference)
AVG (n = 1,423) 1.29 (1.12–1.47) <0.001 1.27 (1.11–1.24) 0.001 1.20 (0.88–1.65) 0.25
CVC (n = 1,685) 3.38 (3.00–3.82) <0.001 2.30 (2.03–2.60) <0.001 2.54 (1.83–3.53) <0.001
Highest tertile of sCCI (≥7)
AVF (n = 3,058) 1.00 (reference) 1.00 (reference) 1.00 (reference)
AVG (n = 968) 1.39 (1.21–1.60) <0.001 1.27 (1.10–1.26) 0.001 1.33 (1.00–1.75) 0.04
CVC (n = 1,134) 3.22 (2.81–3.69) <0.001 2.01 (1.75–2.30) <0.001 1.43 (1.08–1.90) 0.01
Table 2. The association between type of vascular access and all-cause mortality risk at different level of 
sCCI. Model 1: Unadjusted. Model 2: Adjusted for age and sex. Model 3: Model 2 + dialysis vintage, BMI, 
predialysis SBP, etiology of ESRD, functional status, history of hypertension, diabetes, or CVDs, hemoglobin, 
serum albumin, and HbA1c. Abbreviation: sCCI, simplified Charlson comorbidity index; HR, hazard ratio; CI, 
confidence interval; AVF, arteriovenous fistula; AVG, arteriovenous graft; CVC, central venous catheter; BMI, 
body mass index; SBP, systolic blood pressure; ESRD, end-stage renal disease; CVD, cardiovascular disease.
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to dialysis that make selection of vascular access type difficult should be taken into consideration. These include 
the impact of age, functional status, vessel suitability for access creation, maturation, complications, expected 
access survival, the competing risk of death for dialysis initiation, and the burden of comorbidity20.
Multiple comorbidities have a great impact on the vasculature, especially on the vessel wall21. The presence of vas-
cular calcification especially reduces the patency of a vascular access and leads to poor clinical outcomes22. Lee et al.23 
reported that pre-existing arterial pathologic changes such as atherosclerosis affect not only the patency of vascular 
access but also increase the risk of cardiovascular mortality. These poor conditions of the vessel wall have an even 
greater effect when patients are concomitant with diabetes or coronary artery disease22,24. The degree of comorbidities 
should thus be taken into account when selecting the most optimal type of vascular access, especially in elderly patients 
who have a high burden of comorbidity. No studies to date have examined the effect of disease burden on the associa-
tion between vascular access type and clinical outcomes. In the current study, we showed that the use of CVC resulted in 
the greatest increase in the risk of all-cause mortality regardless of the degree of comorbidity. However, the use of AVG 
resulted in inferior survival rates compared with the use of AVF only in patients with the highest sCCI. When the use 
of AVF and AVG was directly compared with sCCI tertiles, the risk of mortality was highest in those with a high sCCI 
using AVG. Several explanations can be deduced as follows. First, as previous studies suggested, AVGs require more 
interventions to maintain patency after access creation as compared with AVFs19. As shown in our study, hospitalization 
rates due to access malfunction were significantly increased with the use of AVG compared to the use of AVF only in the 
Figure 3. The adjusted risk for all-cause mortality according to combination group of sCCI tertile and the 
type of vascular access (AVF vs. AVG). *Model was adjusted for age, sex, dialysis vintage, body mass index, 
predialysis systolic blood pressure, etiology of end-stage renal disease, functional status, history of hypertension, 
diabetes, or cardiovascular diseases, hemoglobin, serum albumin, and HbA1c. Abbreviation: AVF, arteriovenous 
fistula; AVG, arteriovenous graft; sCCI, simplified Charlson comorbidity index; CI, confidence interval.
Number of 
hospitalizations† Access malfunction Access infection
Mean ± SD Case (%)† OR (95% CI)* P Case (%)† OR (95% CI)* P
Lowest tertile of sCCI (4–5) 375 (3.8) 57 (0.6)
AVF (n = 6,748) 0.6 ± 2.4 184 (2.7) 1.00 (reference) 29 (0.4) 1.00 (reference)
AVG (n = 1,515) 0.7 ± 1.2 79 (5.2) 1.65 (0.89–3.03) 0.11 15 (1.0) 4.41 (1.35–14.45) 0.01
CVC (n = 1,528) 1.0 ± 1.3 112 (7.3) 2.83 (1.62–4.94) <0.001 13 (0.9) 1.53 (0.35–6.65) 0.57
Middle tertile of sCCI (6) 395 (4.8) 57 (0.7)
AVF (n = 5,041) 0.8 ± 1.7 181 (3.6) 1.00 (reference) 18 (0.40 1.00 (reference)
AVG (n = 1,423) 1.0 ± 2.8 74 (5.2) 1.27 (0.80–2.04) 0.31 24 (1.7) 5.00 (1.57–15.90) 0.01
CVC (n = 1,685) 1.2 ± 2.3 140 (8.3) 2.22 (1.41–3.48) 0.001 15 (0.9) 2.74 (0.58–12.85) 0.20
Highest tertile of sCCI (≥7) 291 (5.6) 66 (1.3)
AVF (n = 3,058) 1.1 ± 1.4 120 (3.9) 1.00 (reference) 19 (0.6) 1.00 (reference)
AVG (n = 968) 1.2 ± 1.3 67 (6.9) 1.74 (1.04–2.92) 0.03 29 (3.0) 3.90 (1.47–10.32) 0.01
CVC (n = 1,134) 1.5 ± 1.4 104 (9.2) 3.76 (2.31–6.11) <0.001 18 (1.6) 1.27 (0.31–5.22) 0.74
Table 3. The association between type of vascular access and hospitalization at different level of sCCI. †P for 
trend < 0.001. *Models were adjusted for age, sex, dialysis vintage, BMI, predialysis SBP, etiology of ESRD, 
functional status, history of hypertension, diabetes, or CVDs, hemoglobin, serum albumin, and HbA1c. 
Abbreviation: sCCI, simplified Charlson comorbidity index; OR, odds ratio; CI, confidence interval; AVF, 
arteriovenous fistula; AVG, arteriovenous graft; CVC, central venous catheter; BMI, body mass index; SBP, 
systolic blood pressure; ESRD, end-stage renal disease; CVD, cardiovascular disease.
6Scientific RepoRtS |         (2019) 9:18156  | https://doi.org/10.1038/s41598-019-54191-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
highest sCCI group. Some studies suggested that the use of AVG might be more beneficial in elderly patients, because 
these patients might not survive long enough to benefit from AVFs25–27. They argued that the advantages of AVFs over 
AVGs are not seen immediately. Although AVGs require more interventions to maintain patency, AVFs require more 
interventions to mature; therefore, overall patency might not differ substantially between the two types of permanent 
access28,29. This remains controversial, and questions still surround the selection of the most optimal type of access for 
elderly patients. Based on the results of our study, we suggest that elderly patients with high comorbidities should main-
tain AVF use or switch to AVF use if they are using AVG, as elderly patients tend to require frequent vascular interven-
tions. Second, the infection rate is much higher with the use of AVG compared to the use of AVF25,30. It is evident from 
the previous study results that the key risk factor for vascular access–associated infection is the type of access itself31. 
Most studies showed that the risk of vascular access infection is highest with CVC use and decreases with use of AVG 
and AVF32–34. In addition, increasing age or multiple comorbid conditions are also significant risk factors for vascular 
access infection35. In our study, hospitalization rates due to access infection were highest with the use of AVG compared 
with the use of AVF as well as CVC across all sCCI groups. It is unclear why hospitalization rates due to access infection 
were higher with use of AVG than with use of CVC, a finding which is contrary to previous study results. However, 
Ravani et al. recently reported that the risk for infectious complication were highest immediately after placement of 
CVC, but this risk declined and become similar among all types of vascular access over time36. In our study, the vas-
cular access types were investigated after several years of their creation in majority of subjects and the total event rates 
of access infection were significantly low (180 cases, 0.8%). Thus, the cautious interpretation is needed that the risk 
of infections complication can show different results from that of initial creation of vascular access. Furthermore, we 
assumed that the patients using CVC had more comorbidities and were at the greatest risk of death, and that this risk 
outweighed the risk of access infection. Nevertheless, the use of AVG showed a higher risk of infection than the use 
of AVF. We thus suggest that elderly patients who are prone to infection should use AVF or switch to AVF from AVG. 
Finally, patients using AVG, especially those with a high burden of comorbidity, were at an increased risk of mortality 
themselves and could not have afforded to create the AVF. In our study, the trend of using AVF was decreased, whereas 
using AVG or CVC was increased as the sCCI increases. This implies that high burden of comorbidities hinder to create 
AVF with native vessels and, conversely, the use of AVG represents being encountered with worse clinical outcomes.
This study has several limitations. First, due to the retrospective study design, a substantial number of patients 
with missing vascular access or comorbidity data were excluded from the analysis. Furthermore, selection bias 
cannot be excluded that clinician likely to have selected a certain vascular access type based on patient charac-
teristics. For instance, clinicians tend to use AVF in patients with less comorbidities and with expectation to 
survive long. In this respect, the results could be driven by those characteristics as opposed to solely by vascular 
access types. Thus, we made multiple adjustment models and classified subjects according to comorbidity burden 
to minimize this bias. Nevertheless, the cautious generalization of our findings to the HD population is needed 
because there might be still unmeasured confounders. Second, the information about vascular access type was 
investigated at the enrollment of Korean Society of Nephrology End-Stage Renal Disease (KSN ESRD) registry, 
not at the initiation of dialysis. Hence, conversion of vascular access to another access type could not be investi-
gated. Most studies focused on access type at the initiation of dialysis or immediately after initiation. However, 
our study has clinical implications, since we evaluated the effect of maintaining vascular access on outcomes. 
Specifically, if elderly patients with high morbidity maintain vascular access with AVG or CVC, immediate con-
version to AVF should be suggested. Third, the comorbidity index was assessed with limited value compared 
to the original CCI, because there was a lack of information on past history such as hemiplegia, specific cancer 
types, connective tissue disease, and acquired immune deficiency syndrome (AIDS) in the KSN ESRD registry. 
However, overall prevalence rates of these diseases were comparably low, which may have had little effect on 
the main outcomes. Finally, the rate of mortality in our cohort could have been underestimated, because death 
reports are collected voluntarily, and the causes of death were extracted from patient records.
In conclusion, in elderly patients undergoing HD with a high burden of comorbidity, the use of AVF may be 
of greater benefit than AVG with respect to survival rates and lower hospitalization rates due to access-associated 
infections. Moreover, the use of CVC is associated with increased risk of mortality and higher hospitalization 
rates due to access malfunction. Thus, in elderly patients using CVC during HD, the change to use of AVF should 
be considered, and in elderly patients with multiple morbidities using AVG, the change to AVF should be consid-
ered for better survival and clinical prognosis.
Methods
Study subjects. This study used data from the KSN ESRD registry, a nationwide database of medical records 
of patients with ESRD from 2001 to 2018. The ESRD registry committee of the KSN launched the official ESRD 
patient registry in 1985. The registry data were collected through an internet program that was opened in 2001 
and revised in 2013 (http://www.ksn.or.kr)37. A total of 111,964 patients undergoing HD were initially screened, 
and 23,100 elderly patients aged ≥65 years were eventually analyzed, excluding cases with insufficient data and 
those which provided no data on vascular access (Supplementary Fig. 1). The use of vascular access at the time 
of study enrollment was investigated, and subjects were classified into three groups according to access type: 
AVF, AVG, and CVC. All participants were enrolled in the study voluntarily, and informed consent was obtained 
in all cases. This study was carried out in accordance with the Declaration of Helsinki and was approved by the 
Institutional Review Board of Inha University Hospital (INHAUH201812015).
Anthropometric and laboratory data. Demographic and clinical data were collected at the time of study 
enrollment. Age, sex, BMI, dialysis vintage, nPCR, HD adequacy (single-pool Kt/V), SBP and DBP, functional 
status, cause of ESRD, and comorbidities including diabetes, hypertension, coronary artery disease, congestive 
heart failure, cerebrovascular disease, and malignancy were recorded. All laboratory data were based on initial 
values entered in the KSN registry.
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Assessment of the simplified Charlson comorbidity index. We assessed comorbidity burden based 
on CCI. The comorbidities that make up the CCI are myocardial infarction, congestive heart failure, periph-
eral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disease, 
peptic ulcer disease, liver disease, diabetes with or without end-organ damage, hemiplegia, moderate to severe 
CKD, tumors including solid tumors, leukemia, or lymphoma, and AIDS38. However, owing to lack of informa-
tion in the study database, we modified original CCI and developed sCCI as follow; the diagnosis of connective 
tissue disease, hemiplegia, and AIDS was not included in the KSN ESRD database, we excluded these items. 
Furthermore, specific tumor type was not investigated, we assigned a score of 2 for any tumor type. Since all 
patients in our dataset had ESRD, we assigned a score of 2 for any subjects and the lowest possible sCCI score 
was 2. Information on comorbidities were obtained by clinicians from the KSN ESRD registry through patient 
histories and reviews of electronic health records based on International Classification of Diseases, 10th Revision 
codes at the time of study enrollment39,40.
Study outcomes. The primary outcome measure was all-cause mortality, and the secondary outcome 
was hospitalization rate due to catheter related malfunction or infection. Of note, there was a possibility of 
over-estimation of patient survival due to the voluntary nature of registration in the ESRD registry, with submis-
sion of death reports could have easily been missed.
Statistical analysis. All statistical analyses were performed with IBM SPSS software for Windows version 
23.0 (IBM Corporation, Armonk, NY, USA) and R software 3.3.1 (http://www.R-project.org). Continuous varia-
bles were expressed as mean ± standard deviation and categorical variables as absolute numbers with percentages. 
All data were tested for normality before statistical analysis. The Kolmogorov–Smirnov test was performed to 
determine the normality of the distribution of parameters. Comparisons between groups were performed using 
analysis of variance or Student’s t-test for continuous variables with normal distributions and the chi-square test 
or Fisher’s exact test for categorical variables. Data that did not show a normal distribution were presented as 
medians with interquartile ranges and were compared using the Mann–Whitney U-test or the Kruskal–Wallis 
test. Cumulative survival rates were estimated with the Kaplan–Meier analysis and a log-rank test. Survival time 
was defined as the time interval between baseline and either the occurrence of outcomes or the last follow-up. 
Patients who died or were lost to follow-up were censored at the date of the last examination. Cox proportional 
hazards models were constructed to determine the independent predictive value of vascular access types in mor-
tality. Logistic regression analysis was performed to evaluate the association between vascular access types and 
the risk of hospitalization. Variables that showed statistical significance in univariable analyses or were considered 
to have clinical significance were included in multivariable models. All results were expressed as HRs or ORs and 
95% CI. For all analyses, a P value < 0.05 was considered statistically significant.
Data availability
Data is available as supplementary information.
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